



Christine Massey <cmssyc@gmail.com>

FOIA request to CDC re: "SARS-COV-2 spike protein" purification

Christine Massey <cmssyc@gmail.com>
To: "FOIA Requests (CDC)" <FOIARequests@cdc.gov>

Fri, Nov 4, 2022 at 1:18 PM

November 4, 2022

To:
Roger Andoh
Freedom of Information Officer
1600 Clifton Rd NE MS T-01
Atlanta, Georgia 30333
Email: FOIARequests@cdc.gov
Phone: 770-488-6277
Fax: 770-488-6200

Dear Roger,

I require access to general records, as per the *Freedom of Information Act*.

Description of Requested Records:

All studies and/or reports in the possession, custody or control of the Centers for Disease Control and Prevention (CDC) and/or the Agency for Toxic Substances and Disease Registry (ATSDR) **describing the alleged "SARS-COV-2 spike protein" being found in nature (i.e in bodily fluid/tissue/excrement of an alleged "SARS-COV-2 host" or a so-called "COVID-19 vaccine" recipient) and purified** (for example: via ultracentrifugation, chromatography), **with purification of particles confirmed via EM imaging** (the EM image(s) must be available and provided).

Please note that I am not requesting studies/reports where researchers failed to **purify** the alleged "**SARS-COV-2 spike protein**" and instead:

- performed an amplification test, and/or
- assembled an in silico "genome", and/or
- cultured unpurified things, and/or
- produced electron microscopy images of unpurified things.

For further clarity, I do not require records that describe something floating in a vacuum; I simply require records that describe its **confirmed purification** (separation from everything else, as per standard laboratory practices for the purification of other very small things) and corresponding EM images.

Please also note that my request is **not limited** to records that were authored by the CDC or ATSDR or that pertain to work done at/by the CDC or ATSDR. Rather, my request includes any record matching the above description, authored by anyone, anywhere, ever.

If any records match the above description of requested records and are currently available to the public elsewhere, please provide enough information about each record so that I may identify and access each one with certainty (i.e. title, author(s), date, journal, where the public may access it). Please provide URLs where possible.

Format:

Pdf documents sent to me via email; I do not wish for anything to be shipped to me.

Contact Information:

Family name: Massey
Given name: Christine
Address: CDC has it on file
Email: cmssyc@gmail.com

Thank you in advance and best wishes,

11/4/22, 1:19 PM

Gmail - FOIA request to CDC re: "SARS-COV-2 spike protein" purification

Christine Massey, M.Sc.



Christine Massey <cmssyc@gmail.com>

Your CDC FOIA Request #23-00196-FOIA

MNHarper@cdc.gov <MNHarper@cdc.gov>
To: cmssyc@gmail.com

Mon, Nov 7, 2022 at 6:26 AM

November 7, 2022

Request Number: 23-00196-FOIA

Dear Ms. Massey:


This is regarding your Freedom of Information Act (FOIA) request of November 4, 2022, for All studies and/or reports in the possession, custody or control of the Centers for Disease Control and Prevention (CDC) and/or the Agency for Toxic Substances and Disease Registry (ATSDR) describing the alleged "SARS-COV-2 spike protein" being found in nature (i.e in bodily fluid/tissue/excrement of an alleged "SARS-COV-2 host" or a so-called "COVID-19 vaccine" recipient) and purified (for example: via ultracentrifugation, chromatography), with purification of particles confirmed via EM imaging (the EM image(s) must be available and provided).

Please see the attached letter.

Sincerely,
CDC/ATSDR FOIA Office
770-488-6399

2 attachments

 **FOIA request to CDC re_ _SARS-COV-2 spike protein_ purification.msg**
99K

 **Acknowledgement (Complex) 30 Days.pdf**
96K



November 7, 2022

Christine Massey

[REDACTED]
Via email: cmssyc@gmail.com

Dear Ms. Massey:

The Centers for Disease Control and Prevention and Agency for Toxic Substances and Disease Registry (CDC/ATSDR) received your attached Freedom of Information Act (FOIA) request dated November 4, 2022. Your request assigned number is 23-00196-FOIA, and it has been placed in our complex processing queue.

In unusual circumstances, an agency can extend the twenty-working-day limit to respond to a FOIA request.

We will require more than thirty working days to respond to your request because we reasonably expect that two or more CDC centers, institutes, and offices (C/I/Os) may have responsive records.

To process your request promptly, please consider narrowing the scope of your request to limit the number of responsive records. If you have any questions or wish to discuss reformulation or an alternative time frame for the processing of your request, you may contact the analyst handling your request Mark Harper at 770-488-8154 or our FOIA Public Liaison, Roger Andoh at 770-488-6277. Additionally, you may contact the Office of Government Services (OGIS) to inquire about the FOIA mediation services they offer. The contact information for OGIS is as follows: Office of Government Information Services; National Archives and Records Administration; 8601 Adelphi Road-OGIS; College Park, Maryland 20740-6001; e-mail at ogis@nara.gov; telephone at 202-741-5770; toll free at 1-877-684-6448; or facsimile at 202-741-5769.

Because you are considered an "Other requester" you are entitled to two hours of free search time, and up to 100 pages of duplication (or the cost equivalent of other media) without charge, and you will not be charged for review time. We may charge for search time beyond the first two hours and for duplication beyond the first 100 pages. (10 cents/page).


If you don't provide us with a date range for your request, the cut-off date for your request will be the date the search for responsive records starts.

You may check on the status of your case on our FOIA webpage <https://foia.cdc.gov/app/Home.aspx> and entering your assigned request number. If you have any questions regarding your request, please contact me at 770-488-8154 or via email at wzj6@cdc.gov..

We reasonably anticipate that you should receive documents by January 26, 2023. Please know that this date roughly estimates how long it will take the Agency to close requests ahead of your request in the queue and complete work on your request.

The actual date of completion might be before or after this estimated date.

Sincerely,

A handwritten signature in black ink, appearing to read 'Roger Andoh', with a stylized flourish at the end.

Roger Andoh
CDC/ATSDR FOIA Officer
Office of the Chief Operating Officer
(770) 488-6399
Fax: (404) 235-1852

23-00196-FOIA



Christine, of the Massey family <cmssyc@gmail.com>

Your CDC FOIA Request #23-00196-FOIA

MNHarper@cdc.gov <MNHarper@cdc.gov>
To: cmssyc@gmail.com

Fri, Dec 9, 2022 at 9:56 AM

December 9, 2022

Request Number: 23-00196-FOIA

Dear Ms. Massey:

This is regarding your Freedom of Information Act (FOIA) request of November 4, 2022, for All studies and/or reports in the possession, custody or control of the Centers for Disease Control and Prevention (CDC) and/or the Agency for Toxic Substances and Disease Registry (ATSDR) describing the alleged "SARS-COV-2 spike protein" being found in nature (i.e in bodily fluid/tissue/excrement of an alleged "SARS-COV-2 host" or a so-called "COVID-19 vaccine" recipient) and purified (for example: via ultracentrifugation, chromatography), with purification of particles confirmed via EM imaging (the EM image(s) must be available and provided).

Please see the attached letter.

Sincerely,
CDC/ATSDR FOIA Office
770-488-6399

 **Final Response - 23-00196.pdf**
223K



December 9, 2022

Christine Massey

Via email: cmssyc@gmail.com

Dear Ms. Massey:

This letter is our final response to your Centers for Disease Control and Prevention and Agency for Toxic Substances and Disease Registry (CDC/ATSDR) Freedom of Information Act (FOIA) request of November 4, 2022, assigned #23-00196-FOIA, for:

All studies and/or reports in the possession, custody or control of the Centers for Disease Control and Prevention (CDC) and/or the Agency for Toxic Substances and Disease Registry (ATSDR) describing the purification of any "COVID-19 virus" (aka "SARS-COV-2", including any alleged "variants" i.e. "B.1.1.7", "B.1.351", "P.1") (for example: via filtration, ultracentrifugation and chromatography), from a cell culture, with purification of particles confirmed via EM imaging (and the image(s) must be included in, or with, the record or publicly available).

For administrative convenience and to fully respond to your request, program staff have provided the following information below with corresponding web links. Program apprises this is the most sufficient response they can provide.

SARS-CoV-2 is the virus that causes coronavirus disease 2019 (COVID-19). Active infection with SARS-CoV-2 is detected by [diagnostic tests](#). Currently there are two types of diagnostic tests – molecular tests that detect the virus's genetic material and antigen tests that detect specific proteins on the surface of the virus. For current data showing the total number of SARS-CoV-2-positive cases and deaths, visit the [CDC COVID-19 Data Tracker](#), which shows cases and deaths in the United States broken down by state and county, daily trends in the number of cases by state, and other parameters.

Evidence of SARS-CoV-2 infection can be found in a study entitled, [Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease](#), which includes electron microscopy images of SARS-CoV-2 in infected lung and upper airway tissues as well as staining of lung and upper airway tissues using an antibody against SARS-CoV-2. The specimens analyzed in this study were from patients with common signs and symptoms associated with COVID-19, including fever, cough, and shortness of breath. All patients had abnormal findings on chest radiographs. There are other similar studies publicly available online. To aid in locating other related studies, please see the articles suggested in the "Similar Articles" and "Cited by" section on the manuscript's [PubMed entry](#).

The SARS-CoV-2 virus may be isolated from human clinical specimens by culturing in cells. In January 2020, CDC [isolated the SARS-CoV-2 virus](#) from a clinical specimen from the first confirmed case of COVID-19 in the United States. There are other similar studies published describing the isolation and characterization of SARS-CoV-2 from human clinical specimens. To aid in locating other related studies, please see the articles suggested in the "Similar Articles" and "Cited by" section on the manuscript's [PubMed entry](#). There are also [several publications](#) documenting SARS-CoV-2 infection and transmission among pre-symptomatic and asymptomatic individuals.


For information about the SARS-CoV-2 genome sequence, see the NIH GenBank website (<https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/>), which includes over 44,000 sequences as of December 7, 2020.

You may contact our FOIA Public Liaison at 770-488-6246 for any further assistance and to discuss any aspect of your request. Additionally, you may contact the Office of Government Information Services (OGIS) at the National Archives and Records Administration to inquire about the FOIA mediation services they offer. The contact information for OGIS is as follows: Office of Government Information Services, National Archives and Records Administration, 8601 Adelphi Road-OGIS, College Park, Maryland 20740-6001, e-mail at ogis@nara.gov; telephone at 202-741-5770; toll free at 1-877-684-6448; or facsimile at 202-741-5769.

If you are not satisfied with the response to this request, you may administratively appeal to the Deputy Agency Chief FOIA Officer, Office of the Assistant Secretary for Public Affairs, U.S. Department of Health and Human Services, via the online portal at <https://requests.publiclink.hhs.gov/App/Index.aspx>. Please mark both your appeal letter and envelope "FOIA Appeal." Your appeal must be electronically transmitted by March 11, 2023.

If you need any further assistance or would like to discuss any aspect of the records provided please contact either our FOIA Requester Service Center at 770-488-6399 or our FOIA Public Liaison at 770-488-6277.

Sincerely,

A handwritten signature in black ink, appearing to read 'Roger Andoh', written in a cursive style.

Roger Andoh
CDC/ATSDR FOIA Officer
Office of the Chief Operating Officer
(770) 488-6399
Fax: (404) 235-1852

23-00196-FOIA



Christine, of the Massey family <cmssyc@gmail.com>

Your CDC FOIA Request #23-00196-FOIA

Christine, of the Massey family <cmssyc@gmail.com>

Fri, Dec 9, 2022 at 9:49 PM

To: MNHarper@cdc.gov

Thank you Mr. Harper.

The letter is in error, it references the wrong request.

#23-00196-FOIA is regarding:

*the alleged "SARS-COV-2 **spike protein**" being found in nature (i.e in bodily fluid/tissue/excrement of an alleged "SARS-COV-2 host" or a so-called "COVID-19 vaccine" recipient)*

but the letter references an earlier request regarding the fake virus.

Christine

[Quoted text hidden]



Harper, Mark Neville (CDC/OCOO/OD)

to me

Dec 12, 2022, 9:06 AM (4 days ago)

Hi Ms. Massey. This is the request 23-00196 and the final response, which includes appeal language.



2 Attachments • Scanned by Gmail

Your CDC FOIA Request #23-00196-FOIA.eml
 275 KB

Your CDC FOIA R...



Harper, Mark Neville (CDC/OCOO/OD)

to me

Dec 12, 2022, 9:06 AM (4 days ago)

Hi Ms. Massey. This is the request 23-00196 and the final response, which includes appeal language.



2 Attachments • Scanned by Gmail

Your CDC FOIA R...

Your CDC FOIA Request #23-00196-FOIA.eml
 313 KB



Christine, of the Massey family <cmssyc@gmail.com>

Your CDC FOIA Request #23-00196-FOIA

Christine, of the Massey family <cmssyc@gmail.com>
To: "Harper, Mark Neville (CDC/OCOO/OD)" <wzj6@cdc.gov>

Mon, Dec 12, 2022 at 1:17 PM

Greetings Mr. Harper,

Your emails of Nov. 7 and Dec. 9 are attached to your last message, but no response letter, so I still need the response letter re the alleged spike protein;

Thanks, best wishes,
Christine

[Quoted text hidden]



Christine, of the Massey family <cmssyc@gmail.com>

Your CDC FOIA Request #23-00196-FOIA

Harper, Mark Neville (CDC/OCOO/OD) <wzj6@cdc.gov>
To: "Christine, of the Massey family" <cmssyc@gmail.com>

Mon, Dec 12, 2022 at 1:40 PM

This is the closing letter. I sent. Let me know if you can't open it.

[Quoted text hidden]

 **Final Response - 23-00196.pdf**
223K



December 9, 2022

Christine Massey

Via email: cmssyc@gmail.com

Dear Ms. Massey:

This letter is our final response to your Centers for Disease Control and Prevention and Agency for Toxic Substances and Disease Registry (CDC/ATSDR) Freedom of Information Act (FOIA) request of November 4, 2022, assigned #23-00196-FOIA, for:

All studies and/or reports in the possession, custody or control of the Centers for Disease Control and Prevention (CDC) and/or the Agency for Toxic Substances and Disease Registry (ATSDR) describing the purification of any "COVID-19 virus" (aka "SARS-COV-2", including any alleged "variants" i.e. "B.1.1.7", "B.1.351", "P.1") (for example: via filtration, ultracentrifugation and chromatography), from a cell culture, with purification of particles confirmed via EM imaging (and the image(s) must be included in, or with, the record or publicly available).

For administrative convenience and to fully respond to your request, program staff have provided the following information below with corresponding web links. Program apprises this is the most sufficient response they can provide.

SARS-CoV-2 is the virus that causes coronavirus disease 2019 (COVID-19). Active infection with SARS-CoV-2 is detected by [diagnostic tests](#). Currently there are two types of diagnostic tests – molecular tests that detect the virus's genetic material and antigen tests that detect specific proteins on the surface of the virus. For current data showing the total number of SARS-CoV-2-positive cases and deaths, visit the [CDC COVID-19 Data Tracker](#), which shows cases and deaths in the United States broken down by state and county, daily trends in the number of cases by state, and other parameters.

Evidence of SARS-CoV-2 infection can be found in a study entitled, [Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease](#), which includes electron microscopy images of SARS-CoV-2 in infected lung and upper airway tissues as well as staining of lung and upper airway tissues using an antibody against SARS-CoV-2. The specimens analyzed in this study were from patients with common signs and symptoms associated with COVID-19, including fever, cough, and shortness of breath. All patients had abnormal findings on chest radiographs. There are other similar studies publicly available online. To aid in locating other related studies, please see the articles suggested in the "Similar Articles" and "Cited by" section on the manuscript's [PubMed entry](#).

The SARS-CoV-2 virus may be isolated from human clinical specimens by culturing in cells. In January 2020, CDC [isolated the SARS-CoV-2 virus](#) from a clinical specimen from the first confirmed case of COVID-19 in the United States. There are other similar studies published describing the isolation and characterization of SARS-CoV-2 from human clinical specimens. To aid in locating other related studies, please see the articles suggested in the "Similar Articles" and "Cited by" section on the manuscript's [PubMed entry](#). There are also [several publications](#) documenting SARS-CoV-2 infection and transmission among pre-symptomatic and asymptomatic individuals.


For information about the SARS-CoV-2 genome sequence, see the NIH GenBank website (<https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/>), which includes over 44,000 sequences as of December 7, 2020.

You may contact our FOIA Public Liaison at 770-488-6246 for any further assistance and to discuss any aspect of your request. Additionally, you may contact the Office of Government Information Services (OGIS) at the National Archives and Records Administration to inquire about the FOIA mediation services they offer. The contact information for OGIS is as follows: Office of Government Information Services, National Archives and Records Administration, 8601 Adelphi Road-OGIS, College Park, Maryland 20740-6001, e-mail at ogis@nara.gov; telephone at 202-741-5770; toll free at 1-877-684-6448; or facsimile at 202-741-5769.

If you are not satisfied with the response to this request, you may administratively appeal to the Deputy Agency Chief FOIA Officer, Office of the Assistant Secretary for Public Affairs, U.S. Department of Health and Human Services, via the online portal at <https://requests.publiclink.hhs.gov/App/Index.aspx>. Please mark both your appeal letter and envelope "FOIA Appeal." Your appeal must be electronically transmitted by March 11, 2023.

If you need any further assistance or would like to discuss any aspect of the records provided please contact either our FOIA Requester Service Center at 770-488-6399 or our FOIA Public Liaison at 770-488-6277.

Sincerely,

A handwritten signature in black ink, appearing to read 'Roger Andoh', written in a cursive style.

Roger Andoh
CDC/ATSDR FOIA Officer
Office of the Chief Operating Officer
(770) 488-6399
Fax: (404) 235-1852

23-00196-FOIA



Christine, of the Massey family <cmssyc@gmail.com>

Dec 12, 2022, 2:27 PM (4 days ago)



to Mark

I can open the file but it's the same letter that you sent me on Dec. 9, and it cites the wrong request (the correct file number but the wrong wording).

On Nov. 4 I filed a FOIA re the alleged spike protein. On Nov 7 you sent me an email and letter labelled "23-00196-FOIA"; the email correctly cited the spike protein request.


On Dec. 9 you sent me an email and letter labelled "23-00196-FOIA"; the email correctly cited the spike protein request, but the letter incorrectly cited the request as being for records of "SARS-COV-2" purification. I still need the response letter regarding records of the alleged spike protein being found in anyone and purified.

Sorry if I wasn't clear earlier.

Christine



3 Attachments • Scanned by Gmail





Christine, of the Massey family <cmssyc@gmail.com>

Your CDC FOIA Request #23-00196-FOIA

Harper, Mark Neville (CDC/OCOO/OD) <wzj6@cdc.gov>
To: "Christine, of the Massey family" <cmssyc@gmail.com>

Tue, Dec 13, 2022 at 8:56 AM

Hi, I can't find the error. Can you copy and paste what pieces you think are an error? I did not include what the you specified that request did not include in closing letter?

[Quoted text hidden]



Christine, of the Massey family <cmssyc@gmail.com>

Your CDC FOIA Request #23-00196-FOIA

Christine, of the Massey family <cmssyc@gmail.com>
To: "Harper, Mark Neville (CDC/OCOO/OD)" <wzj6@cdc.gov>

Tue, Dec 13, 2022 at 10:07 AM

Sure.

Re "23-00196-FOIA", my Nov. 4 "request", and the Nov 7 acknowledgement email and the Dec. 9 email included the following verbiage regarding the alleged spike protein:

All studies and/or reports in the possession, custody or control of the Centers for Disease Control and Prevention (CDC) and/or the Agency for Toxic Substances and Disease Registry (ATSDR) describing the alleged "SARS-COV-2 spike protein" being found in nature (i.e in bodily fluid/tissue/excrement of an alleged "SARS-COV-2 host" or a so-called "COVID-19 vaccine" recipient) and purified (for example: via ultracentrifugation, chromatography), with purification of particles confirmed via EM imaging (the EM image(s) must be available and provided).

But the Dec. 9 letter includes the following, which is unrelated and from a different "request" regarding the alleged/fake virus:

All studies and/or reports in the possession, custody or control of the Centers for Disease Control and Prevention (CDC) and/or the Agency for Toxic Substances and Disease Registry (ATSDR) describing the purification of any "COVID-19 virus" (aka "SARS-COV-2", including any alleged "variants" i.e. "B.1.1.7", "B.1.351", "P.1") (for example: via filtration, ultracentrifugation and chromatography), from a cell culture, with purification of particles confirmed via EM imaging (and the image(s) must be included in, or with, the record or publicly available).

So I need a final response letter that includes the proper wording.

Cheers,
Christine

[Quoted text hidden]



Christine, of the Massey family <cmssyc@gmail.com>

Your CDC FOIA Request #23-00196-FOIA

Christine, of the Massey family <cmssyc@gmail.com>
To: "Harper, Mark Neville (CDC/OCOO/OD)" <wzj6@cdc.gov>

Thu, Dec 15, 2022 at 12:13 PM

p.s.

hopefully this will help you better understand the issue around the alleged "SARS-COV-2 spike protein", and what i am **not** looking for:

in every paper that my colleagues and/or i have seen, where authors alleged to have studied the alleged SARS-COV-2 spike protein, they have used a "recombinant" aka lab-created "spike protein" that was created in order to study "it"; this has fooled most people into thinking that they studied a protein from the imaginary virus;

none of the papers we've seen involve a "spike protein" that was actually found in any people;

i should have pointed this out in the "request"; regardless, the "request" still clearly states what i'm looking for:

All studies and/or reports in the possession, custody or control of the Centers for Disease Control and Prevention (CDC) and/or the Agency for Toxic Substances and Disease Registry (ATSDR) describing the alleged "SARS-COV-2 spike protein" being found in nature (i.e. in bodily fluid/tissue/excrement of an alleged "SARS-COV-2 host" or a so-called "COVID-19 vaccine" recipient) and purified (for example: via ultracentrifugation, chromatography), with purification of particles confirmed via EM imaging (the EM image(s) must be available and provided).

thanks and cheers,
Christine

[Quoted text hidden]



Christine, of the Massey family <cmssyc@gmail.com>

Your CDC FOIA Request #23-00196-FOIA

Harper, Mark Neville (CDC/OCOO/OD) <wzj6@cdc.gov>
To: "Christine, of the Massey family" <cmssyc@gmail.com>

Fri, Dec 16, 2022 at 8:37 AM

Thanks Ms. Massey. You have appeal rights in most of your closing letters.

[Quoted text hidden]



Christine, of the Massey family <cmssyc@gmail.com>

Your CDC FOIA Request #23-00196-FOIA

Harper, Mark Neville (CDC/OCOO/OD) <wzj6@cdc.gov>
To: "cmssyc@gmail.com" <cmssyc@gmail.com>

Fri, Dec 16, 2022 at 8:39 AM

Checked. You have appeal rights in this request's closing letter attached.

[Quoted text hidden]

 **Final Response - 23-00196.pdf**
223K



December 9, 2022

Christine Massey

Via email: cmssyc@gmail.com

Dear Ms. Massey:

This letter is our final response to your Centers for Disease Control and Prevention and Agency for Toxic Substances and Disease Registry (CDC/ATSDR) Freedom of Information Act (FOIA) request of November 4, 2022, assigned #23-00196-FOIA, for:

All studies and/or reports in the possession, custody or control of the Centers for Disease Control and Prevention (CDC) and/or the Agency for Toxic Substances and Disease Registry (ATSDR) describing the purification of any "COVID-19 virus" (aka "SARS-COV-2", including any alleged "variants" i.e. "B.1.1.7", "B.1.351", "P.1") (for example: via filtration, ultracentrifugation and chromatography), from a cell culture, with purification of particles confirmed via EM imaging (and the image(s) must be included in, or with, the record or publicly available).

For administrative convenience and to fully respond to your request, program staff have provided the following information below with corresponding web links. Program apprises this is the most sufficient response they can provide.

SARS-CoV-2 is the virus that causes coronavirus disease 2019 (COVID-19). Active infection with SARS-CoV-2 is detected by [diagnostic tests](#). Currently there are two types of diagnostic tests – molecular tests that detect the virus's genetic material and antigen tests that detect specific proteins on the surface of the virus. For current data showing the total number of SARS-CoV-2-positive cases and deaths, visit the [CDC COVID-19 Data Tracker](#), which shows cases and deaths in the United States broken down by state and county, daily trends in the number of cases by state, and other parameters.

Evidence of SARS-CoV-2 infection can be found in a study entitled, [Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease](#), which includes electron microscopy images of SARS-CoV-2 in infected lung and upper airway tissues as well as staining of lung and upper airway tissues using an antibody against SARS-CoV-2. The specimens analyzed in this study were from patients with common signs and symptoms associated with COVID-19, including fever, cough, and shortness of breath. All patients had abnormal findings on chest radiographs. There are other similar studies publicly available online. To aid in locating other related studies, please see the articles suggested in the "Similar Articles" and "Cited by" section on the manuscript's [PubMed entry](#).

The SARS-CoV-2 virus may be isolated from human clinical specimens by culturing in cells. In January 2020, CDC [isolated the SARS-CoV-2 virus](#) from a clinical specimen from the first confirmed case of COVID-19 in the United States. There are other similar studies published describing the isolation and characterization of SARS-CoV-2 from human clinical specimens. To aid in locating other related studies, please see the articles suggested in the "Similar Articles" and "Cited by" section on the manuscript's [PubMed entry](#). There are also [several publications](#) documenting SARS-CoV-2 infection and transmission among pre-symptomatic and asymptomatic individuals.


For information about the SARS-CoV-2 genome sequence, see the NIH GenBank website (<https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/>), which includes over 44,000 sequences as of December 7, 2020.

You may contact our FOIA Public Liaison at 770-488-6246 for any further assistance and to discuss any aspect of your request. Additionally, you may contact the Office of Government Information Services (OGIS) at the National Archives and Records Administration to inquire about the FOIA mediation services they offer. The contact information for OGIS is as follows: Office of Government Information Services, National Archives and Records Administration, 8601 Adelphi Road-OGIS, College Park, Maryland 20740-6001, e-mail at ogis@nara.gov; telephone at 202-741-5770; toll free at 1-877-684-6448; or facsimile at 202-741-5769.

If you are not satisfied with the response to this request, you may administratively appeal to the Deputy Agency Chief FOIA Officer, Office of the Assistant Secretary for Public Affairs, U.S. Department of Health and Human Services, via the online portal at <https://requests.publiclink.hhs.gov/App/Index.aspx>. Please mark both your appeal letter and envelope "FOIA Appeal." Your appeal must be electronically transmitted by March 11, 2023.

If you need any further assistance or would like to discuss any aspect of the records provided please contact either our FOIA Requester Service Center at 770-488-6399 or our FOIA Public Liaison at 770-488-6277.

Sincerely,

A handwritten signature in black ink, appearing to read 'Roger Andoh', written in a cursive style.

Roger Andoh
CDC/ATSDR FOIA Officer
Office of the Chief Operating Officer
(770) 488-6399
Fax: (404) 235-1852

23-00196-FOIA



Christine, of the Massey family <cmssyc@gmail.com>

Your CDC FOIA Request #23-00196-FOIA

Christine, of the Massey family <cmssyc@gmail.com>
To: "Harper, Mark Neville (CDC/OCOO/OD)" <wzj6@cdc.gov>

Fri, Dec 16, 2022 at 9:33 AM

Dear Mark,

So you are willfully leaving the letter as is, knowing that the paragraph you cited is from an entirely different FOI and thus the letter is false and misleading?

If so, I will simply publish all of our emails, and this will reflect extremely poorly on you and the CDC.

And I'm quite certain this is a violation of USC, probably multiple violations in fact.

Christine

[Quoted text hidden]



Christine, of the Massey family <cmssyc@gmail.com>

Your CDC FOIA Request #23-00196-FOIA

MNHarper@cdc.gov <MNHarper@cdc.gov>
To: cmssyc@gmail.com

Fri, Dec 16, 2022 at 10:35 AM

December 16, 2022

Request Number: 23-00196-FOIA

Dear Ms. Massey:

This is regarding your Freedom of Information Act (FOIA) request of November 4, 2022.

Please see the attached letter.

Sincerely,
CDC/ATSDR FOIA Office
770-488-6399

 **Final Response Revised 23-00196.pdf**
221K



Centers for Disease Control
and Prevention (CDC)
Atlanta GA 30333
December 16, 2022

Ms. Christine Massey



Via email: cmssyc@gmail.com

Dear Ms. Massey:

This letter is in response to your Centers for Disease Control and Prevention and Agency for Toxic Substances and Disease Registry (CDC/ATSDR) Freedom of Information Act (FOIA) request 23-00196 of November 4, 2022:

Dear Roger,

I require access to general records, as per the Freedom of Information Act.

Description of Requested Records:

All studies and/or reports in the possession, custody or control of the Centers for Disease Control and Prevention (CDC) and/or the Agency for Toxic Substances and Disease Registry (ATSDR) describing the alleged "SARS-COV-2 spike protein" being found in nature (i.e in bodily fluid/tissue/excrement of an alleged "SARS-COV-2 host" or a so-called "COVID-19 vaccine" recipient) and purified (for example: via ultracentrifugation, chromatography), with purification of particles confirmed via EM imaging (the EM image(s) must be available and provided).

Please note that I am not requesting studies/reports where researchers failed to purify the alleged "SARS-COV-2 spike protein" and instead:

- performed an amplification test, and/or*
- assembled an in silico "genome", and/or*
- cultured unpurified things, and/or*
- produced electron microscopy images of unpurified things.*

For further clarity, I do not require records that describe something floating in a vacuum; I simply require records that describe its confirmed purification (separation from everything else, as per standard laboratory practices for the purification of other very small things) and corresponding EM images.

Please also note that my request is not limited to records that were authored by the CDC or ATSDR or that pertain to work done at/by the CDC or ATSDR. Rather, my request includes any record matching the above description, authored by anyone, anywhere, ever.

If any records match the above description of requested records and are currently available to the public elsewhere, please provide enough information about each record so that I may identify and access each one with certainty (i.e. title, author(s), date, journal, where the public may access it). Please provide URLs where possible.

Format:

Pdf documents sent to me via email; I do not wish for anything to be shipped to me.

Contact Information:

Family name: Massey

Given name: Christine

Address: CDC has it on file

Email: cmssyc@gmail.com

For administrative convenience and to fully respond to your request, program staff have provided the following information below with corresponding web links. Program apprises this is the most sufficient response they can provide.

SARS-CoV-2 is the virus that causes coronavirus disease 2019 (COVID-19). Active infection with SARS-CoV-2 is detected by [diagnostic tests](#). Currently there are two types of diagnostic tests – molecular tests that detect the virus's genetic material and antigen tests that detect specific proteins on the surface of the virus. For current data showing the total number of SARS-CoV-2-positive cases and deaths, visit the [CDC COVID-19 Data Tracker](#), which shows cases and deaths in the United States broken down by state and county, daily trends in the number of cases by state, and other parameters.

Evidence of SARS-CoV-2 infection can be found in a study entitled, [Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease](#), which includes electron microscopy images of SARS-CoV-2 in infected lung and upper airway tissues as well as staining of lung and upper airway tissues using an antibody against SARS-CoV-2. The specimens analyzed in this study were from patients with common signs and symptoms associated with COVID-19, including fever, cough, and shortness of breath. All patients had abnormal findings on chest radiographs. There are other similar studies publicly available online. To aid in locating other related studies, please see the articles suggested in the "Similar Articles" and "Cited by" section on the manuscript's [PubMed entry](#).

The SARS-CoV-2 virus may be isolated from human clinical specimens by culturing in cells. In January 2020, CDC [isolated the SARS-CoV-2 virus](#) from a clinical specimen from the first confirmed case of COVID-19 in the United States. There are other similar studies published describing the isolation and characterization of SARS-CoV-2 from human clinical specimens. To aid in locating other related studies, please see the articles suggested in the "Similar Articles" and "Cited by" section on the manuscript's [PubMed entry](#). There are also [several publications](#) documenting SARS-CoV-2 infection and transmission among pre-symptomatic and asymptomatic individuals.

For information about the SARS-CoV-2 genome sequence, see the NIH GenBank website (<https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/>), which includes over 44,000 sequences as of December 7, 2020.

You may contact our FOIA Public Liaison at 770-488-6246 for any further assistance and to discuss any aspect of your request. Additionally, you may contact the Office of Government Information Services (OGIS) at the National Archives and Records Administration to inquire about the FOIA mediation services they offer. The contact information for OGIS is as follows: Office of Government Information Services, National Archives and Records Administration, 8601 Adelphi Road-OGIS, College Park, Maryland 20740-6001, e-mail at ogis@nara.gov; telephone at 202-741-5770; toll free at 1-877-684-6448; or facsimile at 202-741-5769.